A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
Phase of Trial: Phase I/II
Latest Information Update: 11 Oct 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Trametinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CheckMate9N9
- Sponsors Bristol-Myers Squibb
- 22 Feb 2018 Planned End Date changed from 23 Nov 2022 to 24 Nov 2022.
- 22 Feb 2018 Planned primary completion date changed from 20 Sep 2021 to 21 Sep 2021.
- 25 Jan 2018 Planned End Date changed from 17 Dec 2022 to 23 Nov 2022.